101. miR-222 confers the resistance of breast cancer cells to Adriamycin through suppression of p27kip1 expression.
- Author
-
Wang, Dan-dan, Li, Jian, Sha, Huan-huan, Chen, Xiu, Yang, Su-jin, Shen, Hong-Yu, Zhong, Shan-liang, Zhao, Jian-hua, and Tang, Jin-hai
- Subjects
- *
GENETICS of breast cancer , *MICRORNA , *GENE expression , *DOXORUBICIN , *DRUG resistance - Abstract
Adriamycin (Adr) is a potent chemotherapeutic agent for chemotherapy of breast cancer patients. Despite impressive initial clinical responses, some developed drug resistance to Adr-based therapy and the mechanisms underlying breast cancer cells resistance to Adr are not well known. In our previous study, in vitro, we verified that miR-222 was upregulated in Adr-resistant breast cancer cells (MCF-7/Adr) compared with the sensitive parental cells (MCF-7/S). Here, miR-222 inhibitors or mimics were transfected into MCF-7 cell lines. RT-qPCR and western blot were used to detect the expression of p27 kip1 . Immunofluorescence showed that miR-222 altered the subcellular location of p27 kip1 in nucleus. MTT was employed to verify the sensitivity of breast cancer cell lines to Adr. Flow cytometry showed the apoptosis and cell cycles of the cells after adding Adr. The results showed that downregulation of miR-222 in MCF-7/Adr increased sensitivity to Adr and Adr-induced apoptosis, and arrested the cells in G1 phase, accompanied by more expressions of p27 kip1 , especially in nucleus. Furthermore, overexpressed miR-222 in MCF-7/S had the inverse results. Taken together, the results found that miR-222 induced Adr-resistance at least in part via suppressing p27 kip1 expression and altering its subcellular localization, and miR-222 inhibitors could reverse Adr-resistance of breast cancer cells. These results disclosed that the future holds much promise for the targeted therapeutic in the treatment of Adr-resistant breast cancer. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF